GeneMind Biosciences Co., Ltd.
PrivateLast Round
Series D
Sep 14, 2026
Est. Valuation
$573.5M
Total Funding Raised
$218M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
GeneMind Biosciences Co., Ltd. is a biotechnology company that develops and manufactures DNA sequencing systems and molecular diagnostic technology platforms for clinical and research applications.
Sector
Healthcare & Life Sciences
Verticals
Biotech Equipment, Medical Devices, Precision Medicine, Biotechnology
Business Model
B2B
Customer Profile
Usage-Based SaaS, Hardware Sales, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
GeneMind Biosciences Co., Ltd. Comparables
Compare GeneMind Biosciences Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cygnus Biosciences (Beijing) Co., Ltd. | 84% | |
| Axbio | 81% | |
| Element Biosciences | 81% |
GeneMind Biosciences Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Sep 14, 2026 | ||||
| Series C Extension | May 28, 2025 | ||||
| Series C | Aug 2, 2023 | ||||
| Series B Extension | Sep 15, 2021 | ||||
| Strategic | Jun 21, 2021 | ||||
Series B | Sep 1, 2020 |
Key People
Founding team and executive leadership
GeneMind Biosciences Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Sincere Capital | Series B |
| Guosheng Hongyuan (Shanghai) Investment Co., Ltd. | Series D |
| Shanghai International Group | Series D |
| Delian Capital | Series D |
| Hunan Provincial Caixin Industrial Fund Management | Series D |
| Shenzhen HTI Group | Series D, Series C |
| Cowin Capital | Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 14, 2026
Raised $89M Series D round
- Aug 21, 2026
Monthly visitors increased 35% MoM, reaching 4K.
GeneMind Biosciences Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about GeneMind Biosciences Co., Ltd.'s valuation, stock price, and market status.
Is GeneMind Biosciences Co., Ltd. a public or private company?
GeneMind Biosciences Co., Ltd. is a private company.
What is the current stock price of GeneMind Biosciences Co., Ltd.?
GeneMind Biosciences Co., Ltd. is a private company with no public stock price. No recent secondary market data is available.
How much is GeneMind Biosciences Co., Ltd. worth (valuation)?
GeneMind Biosciences Co., Ltd.'s valuation is estimated at $573.5M based on funding round data.
Can I buy GeneMind Biosciences Co., Ltd. stock?
GeneMind Biosciences Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was GeneMind Biosciences Co., Ltd.'s last funding round?
GeneMind Biosciences Co., Ltd.'s most recent funding round was Series C Extension on May 28, 2025.
Who are the main investors in GeneMind Biosciences Co., Ltd.?
Key investors in GeneMind Biosciences Co., Ltd. include Cowin Capital.
Will GeneMind Biosciences Co., Ltd. IPO soon?
No public IPO plans have been announced for GeneMind Biosciences Co., Ltd..
How can I track GeneMind Biosciences Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor GeneMind Biosciences Co., Ltd.'s secondary market activity and sign up for updates.